Poor Outcome of Acute Respiratory Infection in Young Children with Underlying Health Condition in Brazil  by Durigon, Giuliana Stravinskas et al.
International Journal of Infectious Diseases 34 (2015) 3–7Poor Outcome of Acute Respiratory Infection in Young Children with
Underlying Health Condition in Brazil
Giuliana Stravinskas Durigon a,b,c,*, Danielle Bruna Leal Oliveira c,
Maria Carolina Calahani Felicio a, Cristiane Finelli a, Maria Fernanda Badue Pereira a,b,
Juliana Gamo Storni a, Raquel Negra˜o Caldeira c, Reni Chehter Berezin d,
Edison Luiz Durigon c, Eitan Naaman Berezin a
aDepartment of Pediatrics, Santa Casa de Miserico´rdia Hospital, Sa˜o Paulo, Brazil. R. Dr. Cesa´rio Motta Jr, 112, Vl. Buarque, Sa˜o Paulo, SP Brazil, zip code:
01220-020
b Infectious Diseases Division, Children’s Institute University of Sa˜o Paulo, HC-FMUSP, Brazil. Av. Dr, Ene´as Carvalho Aguiar, 647. Sa˜o Paulo, SP, Brazil. zip code:
05403-000
cDepartment of Microbiology, Institute of Biomedical Science, University of Sa˜o Paulo, Brazil. Av. Prof. Lineu Prestes, 1374 - Ed. Biome´dicas II Cidade
Universita´ria - Sa˜o Paulo - SP – Brazil zip code 05508-900
d Statistics consultant. Av. Roberto Lorenz, 482, Jd Guedala, Sa˜o Paulo, SP Brazil, zip code: 05611-050
A R T I C L E I N F O
Article history:
Received 22 October 2014
Received in revised form 28 February 2015
Accepted 2 March 2015
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Respiratory virus
Children
Acute respiratory tract infection
underlying disease
S U M M A R Y
Objectives: It is well established that respiratory viruses are an important cause of hospitalizations in
young children worldwide, but data are limited on the contribution of speciﬁc viruses to severe illness in
South America. We describe clinical and laboratory ﬁndings from prospective surveillance for acute
respiratory infections at a tertiary hospital in Sa˜o Paulo, Brazil.
Methods: We screened children < 2 years old with acute respiratory tract infections admitted to an
urban tertiary hospital for respiratory viruses from March 2008 through February 2010, using
polymerase chain reaction assays.
Results: Respiratory viruses were identiﬁed in 378 (53%) of the 715 samples analyzed. Respiratory
syncytial virus was the most commonly identiﬁed virus (52%), followed by adenovirus (27%) and Human
metapneumovirus (12%). More than one virus was identiﬁed in 19% of specimens. Almost half of the
samples (46%) were from children with underlying health conditions. We demonstrated that compared
to the previously healthy group, those with comorbidities had a worse outcome in terms of severity,
with prolonged hospital stay and more need of intensive care.
Conclusion: Identiﬁcation of this high-risk population along with strategies for fast diagnosis might each
help to reduce morbidity and mortality in this group.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).syncytial virus (RSV) remains the leading cause of lower respiratory
tract infection (LRTI) in young children, especially those under
12 months,2 other viruses, such as human metapneumovirus,
inﬂuenza, parainﬂuenza and adenovirus, are also associated with
LRTI.3 Great effort has been done to improve viral diagnostic
methods in an attempt to identify the causative agents of the most
common clinical syndromes, such as bronchiolitis and pneumonia.
In this scenario of multiple viruses causing the same spectrum of
disease, diagnostic tests are helpful for identifying possible
etiologies, which may ultimately help target prevention and
treatment strategies. In addition to the agent, the host also plays
an important role in determining outcomes.4,5
Therapeutic and preventive strategies available nowadays
against respiratory viruses are still limited. Inﬂuenza vaccinesciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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RSV (palivizumab) can help to reduce inﬂuenza and RSV infection
and morbidity, but still leaves uncovered most of the acute
respiratory virus infection burden. Moreover it’s been demon-
strated that inﬂuenza vaccine’s efﬁcacy is lower than desirable in
young infants6,7 and that palivizumab is cost-effective mostly in
high-risk population.8 Antivirals used for inﬂuenza treatment,
such as neuraminidase inhibitors, can shorten the duration of
symptoms and help to reduce related complications, but have their
efﬁcacy linked to the timing of drug prescription.9
Young children with underlying diseases or risk factors, with
emphasis on those with a history of premature birth, congenital
heart and lung disease, are at greater risk for unfavorable outcomes
when infected with a respiratory virus.10 Therefore, most of
available preventive and treatment drugs are directed to this
special population, although the majority of these strategies have
high cost and /or limited efﬁcacy. Active virus surveillance
allowing good seasonality planning and accessible virus detection
tools for etiological deﬁnition of the respiratory syndromes can
lead to a more rational usage of these strategies.
We describe clinical and laboratory ﬁndings from a prospective
surveillance of hospitalizations due to acute respiratory infection
in young children at a tertiary hospital in Sa˜o Paulo, Brazil,
comparing outcomes in infants with underlying disease to those
previously healthy.
2. Patients and Methods
2.1. Study design
In 2008, we started a prospective surveillance system of acute
respiratory infections (ARI) in children under two years of age at
a university hospital in Sa˜o Paulo city, Brazil. This analysis includes
clinical, epidemiological and laboratory data collected during the
two-year time period from March 1, 2008 through February 28,
2010.
Surveillance was conducted in the Pediatrics Department of
Santa Casa de Miserico´rdia Hospital; a tertiary care center that
receives patients referred from other centers and serves as a
primary hospital for surrounding communities. Enrollment and
sample collection was performed Monday through Friday from
8:00 a.m. to 12:00 p.m. Children under two years-old were eligible
for enrollment if they were admitted to the hospital and had acute
respiratory symptoms of cough and/or difﬁcult breathing or had
an admitting diagnosis of bronchiolitis, pneumonia, wheezing,
croup, pertussis, paroxysmal cough, apnea and cyanosis. An illness
was considered associated with a speciﬁc pathogen if it was
detected by polymerase chain reaction assays (PCR) as described
below. The unit of analysis was hospitalizations, so individuals
may be enrolled more than once over the surveillance period.
Information regarding symptoms, history of underlying health
conditions and immunization status, were collected from parent/
guardian interview and medical records. Antibiotic use, length of
hospital stay, oxygen use, need for intensive care and mechanical
ventilation data were retrieved from medical records.
After obtaining consent for enrollment and specimen collection
from parents/guardians, a single nasopharyngeal aspirate (NPA)
was obtained during each hospitalization by a respiratory
technician. NPAs were kept under refrigeration at 4-6 8C within
one to ﬁve hours and were then divided into three cryotubes per
sample and stored in liquid nitrogen. Weekly, specimens were
sent to the virology laboratory of the University of Sa˜o Paulo for
detection of respiratory viruses by PCR. All samples were tested for
the following: respiratory syncytial virus (RSV), human metap-
neumovirus (hMPV), parainﬂuenza virus 1, 2 and 3 (PIV1-3),
inﬂuenza virus A and B (IA, IB) and adenovirus (ADV). 2009pandemic inﬂuenza A H1N1 (IA-pH1N1) was tested in samples
obtained during the months of January 2009 through February
2010. PCR and reverse transcription (RT)-PCR assays were
developed using Gene Scan analysis with primers previously
described.11–15 IA-p H1N1 was detected by real time PCR assay
developed by the Center for Disease Control and Prevention (CDC
RT-qPCR Swine Flu Panel).16 The protocol speciﬁed that samples
should be collected within 24 h of admission. If ordered by a
clinician, the results of blood cultures were also recorded.
Vaccination in Brazil is public and accessible to all citizens.
Private clinics are permitted and can provide vaccines and other
prophylaxis not included in the National Immunization Program
(NIP). The Brazilian NIP provides inﬂuenza vaccine to all children
from 6 months to 5 years of age and all age groups with underlying
conditions or risk factors.17 There is a recent federal recommen-
dation for RSV prophylaxis. Nevertheless, some states, including
Sa˜o Paulo where this study was carried out, have speciﬁc
recommendations regarding RSV prophylaxis and provide, free
of charge, palivizumab with 5 doses during the seasonality for
infants born premature, under 12 months if  28 weeks of
gestational age (WGA) and all children < 2 years of age with
chronic lung disease or severe congenital heart disease since
2007.18 The Brazilian Pediatric Society19 recommends universal
inﬂuenza vaccination to all children older than 6 months and
extends RSV prophylaxis to premature infants born  31 weeks
and 6 days, infants with neuromuscular diseases, severe immuno-
suppression, and congenital abnormalities of the airways. Palivi-
zumab should also be considered in a 3 doses regimen for those
premature infants born with a gestational age of 32 weeks to
34 weeks and 6 days with at least one risk factor and born 3 months
before or during RSV season.19
The study was approved by the Research Ethics Committee of
Santa Casa de Miserico´rdia Hospital and by the University of Sa˜o
Paulo. Written informed consent was obtained from the parent or
guardian of each child enrolled in the study.
2.2. Data analysis
Data analysis was limited to enrolled children who had a
respiratory specimen collected according to the study protocol
criteria. Categorical variables were compared using x2 test or
Fischer’s exact test, when appropriated. Student t test, Mann-
Whitney test or the One-way ANOVA were used for the continuous
variables. Odds ratio was determined to associate underlying
conditions with hospitalization by speciﬁc respiratory virus. A
multivariate logistic regression model was performed to take into
account the other known risk factors for severe disease and need
of intensive care. Age and hospital days were not normally
distributed. Mann-Whitney U test was used to compare age and
hospital days in the group of healthy versus underlying disease. All
the analyses were performed with SPSS software, version
17.0. Statistical signiﬁcance was considered when p < 0.05.
3. Results
3.1. Surveillance population and laboratory analysis
During the surveillance period, there were 760 hospitalized
patients who met the eligibility criteria. Of those eligible, all had an
NPA obtained, but 41 specimens were obtained >24 hours after
admission and 4 specimens were excluded due to inadequate
sample collection. Therefore, we included 715 (94%) specimens
from all eligible patients, adding up to a total of 622 individuals.
Respiratory viruses were identiﬁed in 378 (53%) of the
715 specimens. RSV was the most commonly identiﬁed virus
(52% of positive specimens), followed by adenovirus (27%), hMPV
Figure 1. Monthly distribution of respiratory viruses (RSV, PIV3 and hMPV) among children hospitalized with acute respiratory tract infection from March 2008 to February
2010, in a tertiary hospital in Sa˜o Paulo city, Brazil. Data are presented in total number of cases.
RSV: human respiratory syncytial virus; hMPV: human metapneumovirus; PIV3: parainﬂuenza virus.
Table 1
Comparison of severity measures in children hospitalized with acute respiratory
tract infection from March 2008 to February 2010, in a tertiary hospital in Sa˜o Paulo
city, Brazil. N=711*.
Underlying Disease
(N=330)
Healthy
(N=381)
p
Age (months)# 8 6 0.000
Hospital days# 7.5 5 0.000
Intensive Care Unit 63 39 0.001
Mechanical ventilation 55 37 0.006
Deaths 7 2 0.089
Antibiotics 178 180 0.074
Positive Blood Cultures 28/285 20/309 0.134
Positive Respiratory Virus 162 212 0.081
Virus Coinfection 25 47 0.036
* Four children from the total of 715, did not have information on history of
underlying disease; # expressed in median;
Statistics: Age and Hospital days: Mann-Whitney U; others x2 and Fisher exact test.
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PIV2 (1%). More than one virus was identiﬁed in 19% of specimens.
A marked seasonality pattern could be observed in the RSV, hMPV
and PIV3 infections (Figure 1).
Overall, 73% of the children hospitalized were under 12 months
and 49% six months or younger. Boys were predominant in this
population (61%). Almost half of the cases (n=330) were from
children with underlying health conditions including but not
limited to history of premature birth (19.9%), congenital heart
disease (12%), chronic lung disease (6.7%) and Down syndrome
(1.7%). Young infants were less likely to have an underlying health
condition than those older than 6 months (p=0.02).
Information regarding use of inﬂuenza vaccine and/or palivi-
zumab for RSV prophylaxis was available for 588 of the
622 children included. We identiﬁed 102 (14%) patients who
met eligibility criteria for RSV prophylaxis, considering recom-
mendations from the Brazilian Pediatric Society.19 In all, only nine
patients had received palivizumab and 17 were previously
vaccinated for inﬂuenza.
3.2. Clinical characteristics and outcomes
Of the 715 hospitalizations, 102 (14%) included intensive care
and 92 (13%) required mechanical ventilation. Of those 102 chil-
dren admitted to the intensive care unit (ICU), 58 had a respiratory
virus detected with RSV being the most commonly detected
among this group (57%), followed by ADV (36%) and PIV (15%).
The most frequent clinical diagnosis was bronchiolitis, attrib-
uted to 230 hospital admissions. Among these, 64% had a
respiratory virus detected, RSV being the most frequent (42.6%).
Detection of more than one virus occurred in 18.4% of cases. The
mean age of the patients with bronchiolitis was 4.8 months,
and only 15% had a history of underlying health condition. In this
group 2.6% required intensive care.
Comparing healthy children (n=381) to those with risk factors
or underlying disease (n=330), we demonstrated that children
with at least one underlying condition were signiﬁcantly older,
stayed longer in the hospital, were more likely to be admitted to
the ICU, were more likely to require mechanical ventilation and
had less virus co-infection (Table 1). Young age and underlyingdiseases were both independent risk factors for hospitalizations
and severe disease. Multivariate analysis with logistic regression
demonstrated that although young age is a risk factor for
admission in intensive care unit, when there is an underlying
condition the risk is increased by 2.5 times.
Looking at only single-virus detections (n=292), a greater
proportion of hospitalizations due to hMPV and PIV infections
were in children with underlying health conditions compared to
others (p=0.003 and p=0.03, respectively). The opposite was
observed with the RSV-related hospitalizations, being the majority
of the patients (58%) previously healthy (p<0.005) (Table 2).
A difference was also observed in the frequency of antibiotics
prescription. Children admitted with an adenovirus (p<0.0005) or
an inﬂuenza virus (p=0.01) received more antibiotics than the
other single-virus detections. Descriptive analysis revealed a
positive association between detection of an adenovirus and need
of intensive care (20.6% ADV positive vs 13.1% ADV negative; chi-
square=4.048; p=0.044). The same was not observed for inﬂuenza
virus (4.9% FLU positive vs 7.5% FLU negative; chi-square=0.901;
p=0.343)
Analyzing infants with diagnosis of bronchiolitis in the single-
virus detection group and comparing situations where RSV was
Table 2
Comparison of number of single viral infections regarding presence of underlying
conditions in children hospitalized with acute respiratory tract infection from
March 2008 to February 2010, in Sa˜o Paulo city, Brazil. N=292.
Underlying Disease
(N=131)
Healthy
(N=161)
p* OR 95% CI
RSV 48 94 <0.0005 0.41 0.26–0.66
hMPV 24 11 0.003 3.06 1.44–6.51
PIV 21 12 0.03 2.37 1.12–5.02
FLU 17 13 0.18 1.70 0.79–3.64
ADV 21 31 0.54 0.81 0.43–1.47
* p chi-square
RSV: human respiratory syncytial virus; hMPV: human metapneumovirus; PIV:
parainﬂuenza virus; FLU: inﬂuenza virus; ADV: adenovirus.
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(n=49), those with RSV had a tendency to be younger (mean of
4.4 months vs 5.5 months; p=0.07) and had fewer comorbidities
(18.4% of underlying conditions in RSV positive vs 36.7% non-RSV;
p=0.004). No difference was found in the need for intensive care
(4% in both groups).
Twelve children had Down syndrome (DS). Congenital heart
disease was present in 11 patients and three patients had a history
of premature birth. Two children, with need of mechanical
ventilation, demanded intensive care. Half of patients had a
respiratory virus detected: hMPV (n=2); IA (n=2); ADV (n=1); IA +
PIV3 + ADV coinfection (n=1). One child died. She had a cyanotic
congenital heart disease and was admitted with a non-alveolar
pneumonia. Blood cultures were negative and hMPV was detected
in the NPA.
Death occurred in nine (1%) of the 622 children. Six of the nine
infants that died had a respiratory virus detected, distributed as
follow: PIV 1 (n=2); hMPV (n=1); RSV (n=1); ADV (n=1) and one
coinfection ADV+RSV. All six had an underlying condition and
required intensive care with mechanical ventilation.
4. Discussion
In this study we evaluated acute respiratory tract infection
leading to hospitalization in young children in a large urban center
in Brazil. We found that a large proportion had underlying
conditions (46%) and that compared to the previously healthy
group, those with comorbidities had more severe outcomes, with
prolonged hospital stay and more need of intensive care.
This special population also behaved in a different manner than
usually described in healthy children. Viruses more associated with
mild symptoms were responsible for acute respiratory failure and
death. This was demonstrated with human metapneumovirus and
parainﬂuenza viruses, usually associated with less severe disease.
Since its discovery, human metapneumovirus has been related
to acute respiratory tract infection in infants worldwide. Heikkinen
et al in a study with 1,338 children under 13 years old with acute
respiratory infection demonstrated a higher incidence rate in
children less than 24 months. In this cohort of previously healthy
children, most of the infected with hMPV had mild or moderate
symptoms, with no need of hospitalization.20
Whereas a high-risk population has a greater chance of having a
poor outcome with viruses that are usually associated with mild
disease (ex: hMPV), it is possible that some respiratory viruses,
such as RSV and ADV, are indeed causing more severe infections,
irrespectively of health condition status.
Marguet et al, in a study evaluating the role of each respiratory
virus in the severity of bronchiolitis, showed that young infants
(median age 2.4 months), previously healthy, had a more severe
presentation when RSV was causing the disease, compared to other
respiratory viruses. On the other hand, when hMPV was causing
bronchiolitis, there was a lower risk of prolonged hospital stay.21We observed signiﬁcant clinical and demographic differences
among the different etiologies in the infants with a diagnosis of
bronchiolitis. When RSV was the causative agent, patients had
fewer comorbidities (p=0.004) and had a tendency of being
younger (p=0.07) than patients with other viruses. Garcia et al in a
publication of risk factors in 4,285 children hospitalized due to
bronchiolitis, comparing RSV versus non-RSV cases, reported
similar results, with more underlying diseases in the group
without RSV (37.5% vs 27% of the RSV positives).22
The detection rate of each of the respiratory viruses studied
was similar to other studies that used comparable diagnostic
methods and study population.23,24 We found a high prevalence of
adenoviruses in our samples, corresponding for the second most
frequent virus detected (27% of the positive samples). The
frequency of adenoviruses varies in the different studies depend-
ing on population selected for screening and on the method
applied for diagnosis. Studies that compare the sensitivity of the
different diagnostic methods, demonstrated that PCR increased
the number of positive cases by three to four times when compared
to immunoﬂuorescent assays.25,26 Nevertheless, local epidemio-
logical characteristics, such as overcrowding or poor sanitary
conditions, may be involved, considering the results published by
Moura et al in Brazil, where 26.6% of the positive samples in
children hospitalized with LRTI had an adenovirus. They screened
for respiratory viruses in a hospital in Sa˜o Paulo city, during the
years of 1995 and 2000 using immunoﬂuorescent assays.27
Bezerra PGM et al.,28 also reported similar results in a
surveillance study carried out in children under 5 years old in a
Northeastern region in Brazil. They collected samples from
407 children (median age 8 months) including hospitalized and
outpatients. RSV was the most frequent pathogen (37.3%), followed
by adenovirus (24.8%) and hMPV (10.3%). Severity analysis
revealed that children with RSV were more likely to be hospitalized
than those infected with other viruses.
Down syndrome is associated with a worse outcome in
respiratory viral infections when compared to healthy infants.
Population-based cohort studies demonstrated a rate of hospitali-
zation in children with DS ﬁve times greater, with a longer hospital
stay than general population, even in the absence of concurrent
risk factors.29,30 Respiratory infections are considered to be the
second cause of death in children with DS.31
There was an underuse of the already available and accessible
prophylaxis for RSV and inﬂuenza viruses in the study population.
Several studies have demonstrated a reduction on hospitalization
rates and mortality in high-risk patients that receive passive
prophylaxis against RSV infection.32,33 In the last ﬁve years there
was an extension in the inclusion criteria of these prophylaxes in
Brazil, with major changes in 2014. Inﬂuenza vaccine was given to
all children under 5 years of age, rather than the previous 2 years of
age limit and palivizumab was incorporated as a national program
and not limited any more to only a minority of the Brazilian states.
These changes, probably a result of improvement in the respiratory
virus surveillance system throughout the country that occurred
as a response to the 2009 pandemic inﬂuenza A H1N1 epidemic,
promoted awareness to health care professionals and the
population to these existing prophylaxes. Some studies already
demonstrate an increment in the number of doses of inﬂuenza
vaccine during the last ﬁve years.14
Our study had some limitations. Samples were not screened for
all of respiratory viruses known to cause lower respiratory tract
infection in this age group, such as rhinovirus, other enteroviruses,
coronaviruses and human bocavirus, which probably explains the
low virus detection rate. Other respiratory pathogens that cause
severe respiratory disease in young infants, such as Bordetella
pertussis, were also not included.34 Therefore, a broader diagnostic
panel, including these agents, might have provided a more precise
G.S. Durigon et al. / International Journal of Infectious Diseases 34 (2015) 3–7 7analysis. However, the viruses included in this study are well-
established causes of respiratory infections, with low rates of viral
coinfection and, except from adenoviruses, low rates of viral
persistence, making it easier to compare the differences in etiology.3
In conclusion, in this study we found that young age and
underlying diseases are both independent risk factors for worse
outcome in children hospitalized with a respiratory virus.
Identiﬁcation of this special population by health care profes-
sionals along with fast diagnosis of the viral nature of the disease,
allow a more aggressive approach that may help to reduce
morbidity and mortality in this group. Recent changes in Brazil,
with broader access of the available prevention tools, through
directed programs for high-risk population, will probably result in
the reduction of severe respiratory infections in children. Future
studies evaluating this new scenario are necessary to conﬁrm the
positive impact of these prophylaxes.
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